Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a pilot study of biomarker evaluation and safety of pre-incisional ketorolac for
patients undergoing surgical resection for non-small cell lung cancer and renal cell
carcinoma. There is significant promise in the use of preoperative ketorolac to decrease the
inflammatory response after surgical resection of tumors, thereby potentially reducing the
risk of distant metastatic tumor spread and improving survival. A total of 56 patients (28
per disease site) will be enrolled into the experimental arm and will receive ketorolac prior
to surgery. About 10 patients will be allocated randomly into a control group, for each
disease site, for a total of 76 patients enrolled. The research will advance scientific
knowledge by studying the safety of a preoperative dose of ketorolac prior to major surgical
resection, which needs to be assessed prior to proceeding with a larger phase II study
designed to evaluate traditional efficacy endpoints such as recurrence and overall survival.